Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

ALT vs CRMD: stock comparison and AI forecast

Altimmune, Inc. (ALT) and Cormedix Inc. (CRMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

ALT Altimmune, Inc.

Price
$2.08 -31.6% · 6M
Market Cap
$405M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

CRMD Cormedix Inc.

Price
$5.23 -34.0% · 6M
Market Cap
$408M
P/E Ratio
2.6x
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

6M · 2026-05-07 → 2026-11-06

Six-month price performance

Closing prices rebased to 100 at the start of the window.

708090100110
ALT -31.6% CRMD -34.0%
ALT · CRMD

Key facts

  • ALT and CRMD have similar market capitalizations ($405M and $408M).
  • Over the last six months ALT returned -31.6% and CRMD -34.0%.
  • CRMD turns 41.4% of its revenue into net income, against -148000.0% for ALT.
  • CRMD carries 0.96 times debt per unit of equity, against 0.11 times for ALT.
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricALTCRMD
Market Cap$405M$408M
P/E Ratio–2.55x
P/B Ratio–0.88x
EPS$-0.85$2.05
Book Value/Share–$5.91
Revenue/Share–$5.80
FCF/Share$-0.39$3.21

Profitability & Margins

MetricALTCRMD
ROE-19.4%40.6%
ROA-17.4%20.7%
ROIC-19.5%30.3%
Gross Margin–90.0%
Operating Margin-161653.2%48.0%
Net Margin-148000.0%41.4%
EBT Margin-148000.0%45.0%
Tax Rate0.7%8.0%

Financial Health

MetricALTCRMD
Current Ratio26.78x2.56x
Quick Ratio–2.36x
D/E Ratio0.11x0.96x
Financial Leverage1.11x1.96x
Interest Coverage-30.2x15.2x
Working Capital$322M$293M

Cash Flow

MetricALTCRMD
Operating Cash Flow-$77M$254M
Free Cash Flow-$77M$250M
Capital Spending-$50K-$4M
OCF Growth YoY–733.6%
FCF Growth YoY–723.5%
FCF/Sales–55.4%
CapEx/Sales–0.8%

Operational Efficiency

MetricALTCRMD
Asset Turnover–0.50x
Receivables Turnover–2.8x
Inventory Turnover–1.2x
Fixed Assets Turnover–57.6x
Days Sales Outstanding–130 days
Days Inventory–312 days
Payables Period–83 days
Cash Conversion Cycle–359 days

Income Statement

MetricALTCRMD
Total Revenue–$452M
Operating Income-$100M$217M
Net Income-$92M$187M
R&D Expense$68M$28M
SG&A Expense–$171M
Cost of Goods Sold–$45M

Dividend & Shareholder Information

MetricALTCRMD
Shares Outstanding195M78M
Net Income Growth–265.9%
EPS Growth–791.3%
FAQ

ALT vs CRMD: stock comparison and AI forecast

Which is bigger, ALT or CRMD?

ALT and CRMD have similar market capitalizations ($405M and $408M).

Which stock performed better over the last six months, ALT or CRMD?

Over the last six months ALT returned -31.6% and CRMD -34.0%.

Which one does Intratio's AI model rank higher, ALT or CRMD?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.